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Abstract
Background: European researchers have underscored associations between single nucleotide polymorphism (SNP)
rs2287622 of the hepatobiliary bile salt export pump (BSEP) gene and the risk of hepatitis C virus (HCV) infection.
The distributions of SNP rs2287622 are racially specific. This study was aimed to preliminarily investigate the distribution
of BSEP gene SNP rs2287622 in the Han patients with chronic HCV-infection (CHC) in Hunan, China.
Methods: BSEP gene SNP rs2287622 of 165 CHC patients, 99 patients with chronic hepatitis B virus infection (CHB) and
99 healthy individuals were analyzed by polymerase chain reaction-restriction fragment length polymorphism analysis
and nucleotide sequencing.
Results: The overall frequencies of the C allele of BESP gene SNP rs2287622 in the CHC patients, CHB patients and
healthy individuals were 74.2, 72.7 and 74.2%, respectively (P > 0.05). The overall odds ratios (ORs) aiming at predicting
CHC risk by comparing the ratios of the frequency distribution of alleles or genotypes in the CHC group with those in
the non-CHC group had no statistical significance (P > 0.05). However, the CHC ORs of CC vs TT, TC vs TT and CC + CT
vs TT among the individuals aged over 40 years were 2.680, 3.122 and 2.824 respectively (P < 0.05), and the higher risk
did not relate to gender, HCV genotypes and presence of HCV-related liver cirrhosis.
Conclusions: Among the Han individuals aged over 40 years in Hunan, China, genotype CC or CT of BSEP gene SNP
rs2287622 may correlate with higher risk of CHC in comparison with genotype TT. Further study with a larger cohort is
essential.
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Background
Hepatitis C is a global pandemic disease. About 185 mil-
lion people are or have previously been infected with
hepatitis C virus (HCV), most of whom develop chronic
hepatitis. Besides, new infections are emerging [1].
Hepatitis C is more prevalent in East Asia, especially in
China, with an estimated prevalence rate of 3.2% in the
general population [2, 3]. Most HCV-infected persons
are unaware that they are at risk for hepatitis C-related
life-threatening diseases such as liver cirrhosis and hepa-
tocellular carcinoma, whose incidences are predicted to
rise in the coming decade [1, 2].
Although it remains unclear, host genetic diversity is
believed to contribute to the susceptibility to HCV infec-
tion or HCV clearance in vivo. In recent years, researches
on different related genetic variants have been published
[4–11]. Since 2009, single nucleotide polymorphisms
(SNPs) of the interleukin-28B gene have been identified as
accurate predictors for therapy response and spontaneous
clearance of HCV infection [4, 5]. Significant associations
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of estrogen receptor α or Toll-like receptor 7 genetic poly-
morphisms with HCV infection susceptibility or viral
clearance among Han Chinese population have been
reported [6, 7].
Since 2011, several European researches have under-
scored associations between a certain SNP, V444A
(HGVS name: NM_003742.2: c.1331 T > C; ref SNP:
rs2287622) in exon 13 of the hepatobiliary bile salt
export pump (BSEP) gene, and the risk of HCV infec-
tion, progression of liver fibrosis and even the virological
response during anti-HCV therapy [8–11]. But their
findings need to be validated by investigation on ex-
tended population, especially on population of different
races. So far, studies on the SNPs of BSEP gene in the
chronic HCV-infected population have been rarely re-
ported in China. The aim of the present study was to
make a preliminary investigation on the distribution of
SNP rs2287622 of BSEP gene in Han patients with
chronic HCV-infection in Hunan, China.
Methods
Patients and control cohort
Random sampling was carried out on patients with
confirmed diagnosis of chronic HCV infection in Liver
Disease Research Center, the Second Xiangya Hospital,
Central South University during 2012 and 2013. The
sample size was estimated by the formula N = Z2 ×
P×(1-P)/E2. The annual amount of the HCV-infected
patients visiting the center is about 1000. The frequency
of allele C in exon 13 c.1331 of BESP gene in Chinese and
Japanese is about 0.70 [12–14]. When the confidence level
was set at 95% (Z0.05 = 1.96) and the sampling error at
10% (E = 0.10), the sample size worked out was 75 for each
year. Additional 10% of the sample size was recruited, and
finally 82 and 83 cases were respectively sampled from the
patients in 2012 and 2013. All the 165 patients were of the
Han nationality.
The diagnostic criteria for the chronic HCV infection
(CHC) were based on the combination of clinical his-
tory, physical examination, imaging and laboratory data
and/or histology. All of the patients finally enrolled in
the study were positive for serum anti-HCV antibodies
and had detectable serum HCV-RNA for at least
6 months. One hundred and seven of them had abnor-
mal liver function indicated by elevated aspartate amino-
transferase (AST) and alanine aminotransferase (ALT)
before anti-HCV treatment. One hundred and thirty-three
cases had ever received systematic anti-HCV therapy by
combination of recombinant interferon-alpha (INF-α)
and ribavirin (RBV). Twenty-six of them adopted
common INF-α/RBV therapeutic scheme and 107
adopted polyethyleneglycolated INF-α (Peg-INF-α)/
RBV therapeutic scheme. Twenty-six of the 165 CHC
patients were diagnosed as HCV-related liver cirrhosis
and 10 of them had been treated with adjusted low
dose Peg-INF-α/RBV therapy.
A total of 99 healthy individuals of the Han nationality
without evidences of hepatitis B virus (HBV) or HCV in-
fections available at the Physical Examination Center of
the hospital on two randomly chosen days (November
21th, 2012 and January 15th, 2013) served as the health
control. Their blood specimens, clinical features and
demographic data were collected.
On January 15th, 2013, 99 chronic hepatitis B
(CHB) cases of Han nationality, including 30 CHB
related liver cirrhosis cases, were randomly selected
from the opening CHB case database in our center, sev-
ering as the CHB control. The database had collected
the demographic data, clinical features and genomic
DNA specimens of more than 1500 CHB patients visit-
ing our center since 2010, all of whom had been HBV
surface antigen (HBsAg) positive for over six months
and had detectable serum HBV DNA when their
genomic DNA samples were collected. Inclusion of
hepatitis B patients into the controls was based on two
facts. Firstly, HBV and HCV are both hepatotropic vi-
ruses and share similar transmission routes and clinical
manifestations. Secondly, having CHB patients as con-
trols is popular in professional researches on CHC, so
is in the similar European research [10].
One hundred and sixty-five CHB and 99 CHB cases
finally enrolled in the study were all confirmed to have
no evidence of co-infection with hepatitis A virus,
hepatitis E virus, Epstein-Barr virus, cytomegalovirus or
human immunodeficiency virus, no detectable anti-delta
antibodies, or no evidence of other chronic liver disease
(autoimmune chronic liver disease, alcoholic liver
disease, drug-induced liver injury, hemochromatosis,
Wilson’s disease, or ɑ1-antitrypsin deficiency). None of
the 165 CHC or 99 CHB cases was co-infected with
HCV and HBV.
The collection of all the demographic data, clinical
features and biological specimens including genomic
DNA from the peripheral blood of the research objects
fulfilled the requirements of medical ethics. The ethical
review committees of the Second Xiangya Hospital of
Central South University approved this study. Guidelines
of the Declaration of Helsinki set by the committees
were strictly followed. Written informed consent was
obtained from all participants.
Clinical features of the patients and control cohort
Serum ALT, AST and total bilirubin of the patients were
measured by a 7600 Series automatic analyzer (Hitachi
High-Tech Co., Japan) according to the manufacturer’s
instructions. Serum anti-HCV was assessed by an en-
zyme linked immunosorbent assay (ELISA) diagnostic
kit (Zhuhai Livzon Diagnostics Inc., China), and HBsAg
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was tested by another ELISA diagnostic kit (Shanghai
Kehua Bio-engineering Co., Ltd., China) according to
the manufacturer’s instructions. Quantitation of plasma
HCV RNA was assessed in 7500 real-time PCR system
(Applied Biosystems Inc., USA) by using HCV RNA
quantitative fluorescence diagnostic kit (Sansure bio-
tech Inc. Ltd, China), and the lower limit of the de-
tection was 25 IU/mL. Quantitation of serum HBV
DNA was assessed in StepOnePlus real-time PCR sys-
tem (Applied Biosystems Inc., USA) by using HBV
DNA quantitative fluorescence diagnostic kit (Sansure
biotech Inc. Ltd, China), and the lower limit of the
detection was 10 IU/mL.
Liver cirrhosis was diagnosed by liver biopsy, or
FibroScan liver stiffness more than 13 kilopascal (kPa)
together with Child-Turcotte-Pugh score more than 7,
or FibroScan liver stiffness more than 13 kPa together
with any two of the following criteria: the presence of
ascites, hepatic encephalopathy, upper gastrointestinal
bleeding, endoscopic detection of gastroesophageal vari-
ces, radiologic imaging of nodular liver or splenomegaly
and peripheral blood platelet count below 100 × 109/L in
the absence of other explanations. Liver stiffness was
measured by the FibroScan® 502 transient elastography
device (Echosens, Paris, France), and the liver stiffness
values were expressed in units of kPa, ranging from 2.5
to 75 kPa. Percutaneous liver histological examination
was performed from the right lobe under real-time ultra-
sound guidance, and the inflammation grades and fibro-
sis stages of the biopsy samples were interpreted by two
experienced hepatopathologists who were blinded to the
clinical data.
Based on the assessment of hepatic encephalopathy
grade, ascites, prothrombin activity, serum albumin and
bilirubin levels, liver cirrhosis severity was assessed in
the cirrhotic cases using a modified Child-Pugh's classifi-
cation system [15, 16]: 5–6 points, grade A; 7–9 points,
grade B; 10–15 points, grade C.
Collection of genomic DNA from peripheral blood
About 5 mL peripheral blood was collected from each pa-
tient into elhylene diamine tetraacetic acid (EDTA)-con-
taining vacationer tubes. Plasma was stored at −70 °C
until HCV RNA loading analysis. Peripheral blood
monouclear cells (PBMCs) were isolated from EDTA-
treated blood by lymphocyte separation medium
(Tianjin Haoyang Biological manufacture Co., Ltd., China)
by centrifugation over density gradient. PBMCs were then
washed three times with phosphate-buffered saline (pH
=7.4), counted and stored at −70 °C for later detection.
Genomic DNA was isolated from a pellet of approxi-
mately 3–5 × 106 PBMCs using EZHighTM-TG DNA
Extraction Kit (Texas BioGene, Inc. USA) according to
the manufacturer’s instructions. The concentrations of
DNA samples were measured using the T6 spectropho-
tometer (Beijing Purkinje General Instrument Co., Ltd.,
China), then the DNA samples were diluted to 10 ng/μl.
Confirmation of SNP rs2287622 genotypes by polymerase
chain reaction-restriction fragment length polymorphism
analysis (PCR-RFLP)
The sequences of the oligonucleotide primers using




PCR was performed in a total volume of 30 μl contain-
ing 60 ng genomic DNA, 0.3 pmol of each primer, 15 μl
2 × Taq MasterMix (0.05 U/μl Taq DNA polymerase, re-
action buffer, 4 mM MgCl2, and 0.4 mM of each dNTP;
Beijing ComWin Biotech Co., Ltd., China), 0.75 units
Pfu DNA Polymerase (recombinant; Beijing ComWin
Biotech Co., Ltd., China) and sterile deionized nuclease-
free water. A PTC-100TM Programmable thermal con-
troller (MJ Research, Inc., USA) was used for PCR with
the following cycling conditions: initial denaturation at
94 °C for 3 min, followed by 35 cycles consisting of de-
naturation at 94 °C for 30 s, annealing at 60 °C for 30 s,
extension at 72 °C for 30 s, and a final extension step at
72 °C for 5 min followed by cooling to 25° for 5 min.
The PCR amplicon fragment was 333 base pairs in
length.
10 μL PCR products were digested by HaeIII restric-
tion endonuclease and buffer R (Fermentas Inc., USA) at
37 °C for 12 h, then the restriction digestion products
for each were separated on 1.5% agarose gel stained with
ethidium bromide for visualization on a ultraviolet
transilluminatior. HaeIII digestion of allele CC yielded
fragments of 127 and 206 base pairs, whereas PCR
amplicons containing the allele TT polymorphism main-
tained 333 base pairs and amplicons containing the allele
TC polymorphism yielded fragments of 127, 206 and
333 base pairs. All of the tests were performed in
duplicate.
Nucleotide sequencing
In order to confirm the accuracy of the detection results
of SNP rs2287622 genotypes by PCR-FRLP, PCR was
performed in triplicate on the genomic DNA samples of
the 165 chronic HCV infection patients, 33 samples
randomly chosen from the 99 chronic HBV infection pa-
tients and 33 from the 99 healthy individuals. The PCR
products were purified with Wizard® SV Gel and PCR
Clean-Up System (Promega Biotech Co., Ltd, USA)
according to the manufacturer’s instructions. Direct se-
quencing of the purified products was performed by
Shanghai Sangon Biotech Co., Ltd., China, with 3730xl
DNA Analyzer and ABI BigDye® Terminator v3.1 Cycle
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Sequencing kit (Applied Biosystems Inc., USA). The se-
quences obtained were compared with the BSEP refer-
ence sequence derived from publicly available databases
provided by NCBI (http://www.ncbi.nlm.nih.gov/) to
confirm the SNP rs2287622 genotypes.
Statistical analysis
All statistical analyses were performed with IBM® SPSS®
Statistics version 20.0. The BSEP SNP rs2287622 geno-
types and clinical features were compared between pa-
tients and control cohort. Chi-squared test, Analysis of
Variance and Student t-test were used for comparisons
between groups and Hardy-Weinberg equilibrium tests
of the genotyping results. Allelic discrimination assay
and association case–control analysis based on gender-,
age-, HCV genotype- or liver cirrhosis-stratified analyses
were performed to investigate the role of the BSEP SNP
rs2287622 genotyping in the susceptibility to HCV infec-
tion, and odds ratios (ORs) were given with 95% confi-
dence intervals (CIs). For all these tests, P value less
than 0.05 was considered statistically significant.
Results
Demographic characteristics and clinical parameters of
the study subjects
Overall, 165 patients with chronic HCV infection, 99
patients with chronic HBV infection and 99 healthy indi-
viduals were included in this study. A summary of
demographic data and clinical parameters of the study
subjects was given in Table 1. All of the participants
were aged 18 years or above. Among the three groups,
gender was equally distributed and average age and BMI
was not significantly different. Serum ALT and AST
levels were comparable between HCV-infected and
HBV-infected patients.
Among the 26 cirrhotic CHC cases, 10 were assessed
as Child-Pugh (C-P) grade A and were treated with low
dose Peg-INF-α/RBV therapy. Nine cases with C-P grade
B and seven cases with C-P grade C received symptom-
atic and supportive treatment other than Peg-IFN-α/
RBV combination therapy. Among the 30 cirrhotic CHB
cases, 12 were assessed as C-P grade A, 10 as grade B
and 8 as grade C. The severity of liver cirrhosis was
statistically comparable between cirrhotic CHC and
cirrhotic CHB cases.
Confirmation of SNP rs2287622 genotypes of BSEP gene
by PCR-RFLP and nucleotide sequencing
The exon 13 and 5′ flanking region of BSEP gene of all
samples were successfully amplified by PCR. RFLP ana-
lysis and nucleotide sequencing of the PCR products
confirmed the SNP rs2287622 genotypes TT, CC and
TC, as the codon of the 444th amino acid had three
polymorphisms as GTC, GCC and heterozygote (see
Fig. 1). Identification findings of the SNP rs2287622
genotypes by PCR-RFLP were completely consistent
with the results by the triplicate PCR and nucleotide
sequencing.
Frequency distribution of BSEP rs2287622 alleles
and genotypes
Frequency distribution of BSEP rs2287622 genotypes
The frequency distribution of BSEP SNP rs2287622 in
the research objects with different ages accorded with
Hardy-Weinbery genetic equilibrium law (P > 0.05),
suggesting that the cohorts were representative of the
targeted population (Table 2).
Frequency distribution of BSEP SNP rs2287622 alleles and
genotypes on age stratification basis
The frequency distribution of BSEP SNP rs2287622
alleles and genotypes in the research subjects was de-
scribed on age stratification basis (Table 2). The overall
frequencies of the C allele of BESP gene SNP rs2287622
in the CHC patients, CHB patients and healthy individ-
uals were 74.2, 72.7 and 74.2%, respectively, indicating
Table 1 Demographic characteristics and clinical parameters of the study subjects
Parmeter CHC CHB Healthy P value
n 165 99 99 –
Gender male (n, %) 88 (53.3) 50 (50.5) 50 (50.5) NS
Age, years (mean ± SD, range) 43.3 ± 11.9 (18–70) 43.5 ± 12.3 (22–67) 40.3 ± 12.2 (18–68) NS
BMI (mean ± SD, range) 23.2 ± 3.9 (16.5–34.6) 22.6 ± 3.5 (18.4–33.9) 23.8 ± 3.4 (17.1–32.3) NS
ALT, IU/L (median ± SD, IQR) 82.0 ± 62.0 (70.2) 94.1 ± 65.1 (83.6) normal NSb
AST, IU/L (median ± SD, IQR) 65.6 ± 40.4 (50.1) 77.4 ± 42.0 (68.0) normal NSb
HCV RNA level, log IU/mL (median ± SD, IQR) 6.08 ± 1.35 (1.51) — — —
HBV DNA level, log IU/mL (median, IQR) — 5.97 ± 1.21 (1.43) — —
BMI body mass index, SD standard deviation, IQR interquartile range, NS non-significant, P > 0.05
aThe clinical data of the patients treated with anti-HCV or anti-HBV therapy were collected at the start point of the treatment, while data of the other patients
were collected on the day when the genomic DNA were collected
bComparisons of serum aminotransferase levels were carried out only between patients with chronic HCV infection and those with chronic HBV infection
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Fig. 1 PCR amplification products of exon 13 of BSEP gene and confirmation of the SNP rs2287622 genotypes by nucleotide sequencing and
RFLP. 1.1 amplification product of exon 13 of BSEP gene. a.DNA Marker I (Shanghai yuanye biotechnology Co., Ltd., China); b, c:cases; d:blank;
e:DNA MarkerVI (Shanghai yuanye bio-technology Co., Ltd., China). 1.2 CC 1.3 TT 1.4 TC: Confirmation of rs2287622 genotypes by nucleotide
sequencing. 1.5 Confirmation of rs2287622 genotypes by RFLP. a.blank; b.100bp DNA Ladder Marker (Beijing BLKW biotechnology Co., Ltd., China);
c. rs2287622 genotype CC; d. rs2287622 genotype TT; e.rs2287622 genotype TC
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Table 3 Frequency distribution of BSEP SNP rs2287622 alleles and genotypes in the research subjects on age stratification basis (n, %)
Alleles or genotypes Overall 18- years old 40- years old
Non-CHC CHC (n = 165) Non-CHC CHC (n = 58) Non-CHC CHC (n = 107)
Health (n = 99) CHB (n = 99) Health (n = 54) CHB (n = 41) Health (n = 45) CHB (n = 58)
Alleles C 147 (74.2) 144 (72.7) 245 (74.2) 85 (78.7) 62 (75.6) 81 (69.8) 62 (68.9) 82 (70.7) 164 (76.6)
T 51 (25.8) 54 (27.3) 85 (25.8) 23 (21.3) 20 (24.4) 35 (30.2) 28 (31.1) 34 (29.3) 50 (23.4)
Genotypes CC 60 (60.6) 57 (57.6) 94 (57.0) 35 (64.8) 24 (58.5) 30 (51.7) 25 (55.6) 33 (56.9) 64 (59.8)
TT 12 (12.1) 12 (12.1) 14 (8.5) 4 (7.4) 3 (7.3) 7 (12.1) 8 (17.8) 9 (15.5) 7 (6.5)
TC 27 (27.3) 30 (30.3) 57 (34.5) 15 (27.8) 14 (34.1) 21 (36.2) 12 (26.7) 16 (27.6) 36 (33.6)
Alleles analysis Overall
Chi-square 0.172 2.391 2.517
P value 0.918 0.302 0.284
CHC vs Non-CHC
Chi-square 0.053 2.156 2.433
P value 0.817 0.142 0.119
Risk of CHC OR
(95%CI) (C vs T)




Chi-square 2.379 2.340a 5.516
P value 0.666 0.674 0.238
CHC vs Non-CHC
Chi-square 2.157 1.892 5.388
P value 0.340 0.388 0.068
Risk of CHC
CC vs TT
Chi-square 0.779 1.395 4.355
P value 0.377 0.238 0.037
OR (95%CI) 1.377 (0.675–2.809) 0.508 (0.163–1.584) 2.680 (1.037–6.924)
CC + TC vs TT
Chi-square 1.270 0.957 5.146
P value 0.260 0.328 0.023
OR (95%CI) 1.488 (0.743–2.979) 0.580 (0.192–1.746) 2.824 (1.118–7.130)
TT + TC vs CC
Chi-square 0.166 1.595 0.264
P value 0.683 0.207 0.607
OR (95%CI) 1.091 (0.718–1.658) 1.530 (0.790–2.963) 0.866 (0.500–1.499)
TC vs TT
Chi-square 1.982 0.284 5.124
P value 0.159 0.594 0.024
OR (95%CI) 1.714 (0.806–3.645) 0.724 (0.221–2.377) 3.122 (1.138–8.567)
CHC patients with chronic HCV infection, CHB patients with chronic HBV infection, Healthy Healthy individuals, OR odds ratio, CI confidence interval
aContinuity Corrected Chi-square
Table 2 Frequency distribution of BSEP SNP rs2287622 genotypes in the research subjects of different age groups
Genotypes 18-years old 30-years old 40-years old 50-years old 60-years old
Non-CHC CHC Non-CHC CHC Non-CHC CHC Non-CHC CHC Non-CHC CHC
Health CHB Health CHB Health CHB Health CHB Health CHB
CC 16 10 12 19 14 18 11 14 37 9 13 20 5 6 7
TT 2 1 1 2 2 6 5 5 4 2 3 3 1 1 0
TC 6 5 10 9 9 11 6 7 17 4 6 11 2 3 8
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no statistical difference (P > 0.05). The odds ratios (ORs)
aiming at predicting CHC risk by comparing the ratios
of the frequency distribution of allele C to T, of genotype
CC, TC or CC + CT to TT, and of genotype TT, TC or
TT + TC to CC in the CHC group with those in the
non-CHC group had no statistical significance (P > 0.05)
(Table 3). However, further data analysis found that
when the research subjects were stratified into 18-
and 40- years old age groups, the ORs of genotype
CC to TT, TC to TT and CC + CT to TT in the 40-
years old age group all had statistical significance (CC
vs TT, OR = 2.680, 95%CI:1.037–6.924, P = 0.037;TC vs
TT, OR = 3.122, 95%CI: 1.138–8.567, P = 0.024; CC+
CT vs TT, OR = 2.824, 95%CI:1.118–7.130, P = 0.023),
indicating that homozygous and heterozygous pres-
ence of C allele was associated with CHC infection.
Nevertheless, for the subjects aged 18- years, it was
not the case.
Frequency distribution of BSEP SNP rs2287622 alleles and
genotypes on gender stratification basis
Further analysis was conducted to explore the CHC risk
of C allele in 40- years old subgroup. First, the gender
differences of the frequency distributions of BSEP SNP
rs2287622 alleles and genotypes were examined. The
analysis showed that there were no statistical differences
in the frequencies of the alleles and genotypes of BESP
SNP rs2287622 between males and females, either for
the overall population or for the 40- years old subgroup
(all P >0.05) (Table 4).
Frequency distribution of BSEP SNP rs2287622 alleles and
genotypes on HCV genotype basis
As described in Table 5, the HCV genotypes distributed
differently between CHC patients aged 18- years and
those aged 40- years, and the proportion of type 1 HCV
infection was statistically higher in CHC patients aged 40-
years (Chi-square =14.035, P = 0.001). So the role of HCV
genotypes in the higher presence of SNP rs2287622 allele
C and genotypes CC and TC in CHC cases aged 40 years
and above was explored. Further analysis was made to ex-
plore whether the higher presence of SNP rs2287622 allele
C and genotypes CC and TC in CHC cases aged 40- years
were associated with HCV type 1 infection. Therefore, the
distribution of the frequencies of the genotypes of BESP
gene SNP rs2287622 was compared among HCV type 1
infected patients, non HCV type 1 infected cases and
those with unknown genotype. No significant difference
was found, either for the overall, or for the 18- or 40-
years age groups (all P >0.05) (Table 5).
Table 4 Frequency distribution of BSEP SNP rs2287622 alleles and genotypes on gender stratification basis
Alleles or genotypes Overall 40- years old
Non-CHC CHC P value Non-CHC CHC P value
CHB Healthy CHB Healthy
Male Female Male Female Male Female Male Female Male Female Male Female
Alleles C 69 75 78 69 132 113 NS 41 41 20 42 78 86 NS
T 31 23 24 27 44 41 19 15 16 12 22 28
Genotypes CC 26 31 33 27 51 43 NS 16 17 12 13 31 33 NS
TT 7 5 6 6 7 7 5 4 5 3 3 4
CT 17 13 12 15 30 27 9 7 6 6 16 20
P value NS NS NS NS NS NS
CHC patients with chronic HCV infection, CHB patients with chronic HBV infection, Healthy Healthy individuals, NS non-significant
All P >0.05
Table 5 Frequency distribution of BSEP SNP rs2287622 genotypes on HCV genotype stratification basis (n, %)
HCV
genotypes
Overall 18- years old 40- years old
n CC TT CT n CC TT CT n CC TT CT
Type 1 59 32 (54.2) 6 (10.2) 21 (35.6) 14 6 (42.9) 1 (7.1) 7 (50.0) 45 26 (57.8) 5 (11.1) 14 (31.1)
Non type 1 20 13 (65.0) 2 (10.0) 5 (25.0) 14 9 (64.3) 2 (14.3) 3 (21.4) 6 4 (66.7) 0 (0.0) 2 (33.3)
Unknown 86 49 (57.0 6 (7.0) 31 (36.0) 30 15 (50.0) 4 (13.3) 11 (36.7) 56 34 (60.7) 2 (3.6) 20 (35.7)
Total 165 94 (57.0) 14 (8.5) 57 (34.5) 58 30 (51.7) 7 (12.1) 21 (36.2) 107 64 (59.8) 7 (6.5) 36 (33.6)
Chi-square 1.388a 2.617a 2.827a
P value 0.846 0.624 0.572
aContinuity Corrected Chi-square
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Frequency distribution of BSEP SNP rs2287622 alleles and
genotypes on cirrhosis stratification basis in CHC and
CHB patients
Among all the 165 CHC cases, 26 had clinical diagnosis
of liver cirrhosis, among which 22 were older than
40 years. So the association of the alleles and genotypes
of BESP SNP rs2287622 with liver cirrhosis was explored
to find whether the predilection potential of C in CHC
cases was due to its close relationship with liver cirrho-
sis. No significant differences in the frequencies of the
alleles and genotypes of BESP gene SNP rs2287622 were
found between CHC and CHB patients with and without
liver cirrhosis (all P >0.05, Table 6).
Discussion
BSEP is a hepatobiliary bile salt transporter on human he-
patocellular canalicular membrane, one of the members of
ATP-binding protein super family. Bile salts are trans-
ported to hepatocytes by Na+−taurocholate cotransport-
ing polypeptide (NTCP) and sodium-independent organic
anion transporting polypeptide (OATP), while they are
transported from hepatocytes into bile canaliculus mainly
by BSEP. BSEP plays an important role in the metabolism
of hepatocellular bile acid [17, 18].
BSEP gene is located in the long arm of human
chromosome 2, 2q24-31. It transcribes an mRNA of
5.5 kb. The expression of BSEP gene is mainly regulated
by the farnesoid X receptor (FXR). Expression and acti-
vation of FXR in the cell is the key to the transcriptional
activation of BSEP gene [18]. There are FXR binding ele-
ments in the promoter of BSEP gene. Many bile acid
components, such as chenodeoxycholic acid (CDCA),
lithocholic acid (LCA), deoxycholic acid (DCA) and cho-
lic acid (CA), represent the native activators of FXR,
among which CDCA can induce the strongest activation.
The metabolic balance of bile acid in the hepatocytes is
maintained by positive regulation on BSEP expression
through activating FXR by bile acid.
In vitro experiments, studies have demonstrated that
DCA and CDCA at physiological concentration increased
the levels of HCV RNA and proteins up to five to ten
folds, while the antagonist of the bile acid receptor or
siRNA targeted at the gene of the bile acid receptor
would reduce the bile acid-mediated increase of HCV
RNA [19–21]. It has been reported that multiple bile
acid components could increase HCV replication by ac-
tivating FXR or EGFR/ERK pathway [21–23]. Meanwhile,
they up-regulated apolipoprotein CII and activated a rate-
limiting enzyme associated with the activation of the lipo-
protein lipase. In these ways, they changed the course of
HCV entering the host cells and the secretion of the virus
particles from the host cells [21–23].
The clinical data indicated that elevated serum bile salt
levels were significantly associated with increased risk of
cirrhosis in patients with chronic HCV infection, and
decreased sustained virological response (SVR) rate in pa-
tients treated with pegylated interferon-α and ribavirin. The
mechanism may involve the block of the signal pathway of
interferon, which is independent of FXR. Hydrophobic bile
acids will inhibit Jak1- and Tyk2-phosphorylation, resulting
in a decreased mRNA and protein expression of IFN-
stimulated genes such as myxovirus resistance protein A
(MxA) or dsRNA-activated protein kinase (PKR) thereby
explaining interferon-ɑ resistance [24].
It has been reported that the polymorphism of BSEP
gene might affect the expression and distribution of BSEP
and transportation of bile acid, and eventually change the
acid bile pool [17, 18, 25]. Studies on patients with intrahe-
patic cholestasis or idiopathic cholestasis during pregnancy
indicated that polymorphism c.1331 T >C (p.V444A) (SNP
rs2287622) in exon 13 of BSEP gene would lead to inhib-
ition of the transportation of bile acid out of the hepato-
cytes [17, 25, 26].
In view of these, the effects of BSEP on the occur-
rence, progression and antiviral treatment response in
chronic hepatitis C were studied. Europeans researches
suggested that the polymorphism of BSEP V444A might
be associated with the HCV infection development, liver
fibrosis progression and long-term treatment response
[8–11]. The few studies needed to be further supported
by researches on extended population.
So far, no researches on the association between BSEP
polymorphism and HCV infection in Chinese population
were reported. Our preliminary study indicated that the
frequency of allele C in BESP exon 13 c.1331 in Han pa-
tients with chronic HCV infection, chronic HBV infection
and healthy individuals were 74.2, 72.7 and 74.2%, respect-
ively, and the distributions of the alleles in the three
groups were in accordance with Hardy-Weinberg equilib-
rium. The frequencies of allele C in the three groups were
not statistically different. Our study suggested that the dis-
tributions of the polymorphism of BSEP SNP rs2287622
Table 6 Frequency distribution of BSEP SNP rs2287622 alleles
and genotypes on cirrhosis stratification basis in CHC and CHB
patients (n, %)
Groups Cirrhosis Alleles Genotypes
C T CC TT TC Total
CHC no 204 74 77 (55.4) 12 (8.6) 50 (36.0) 139 (100)
yes 41 11 17 (65.4) 2 (7.7) 7 (26.9) 26 (100)
Total 245 85 94 (57.0) 14 (8.5) 57 (34.5) 165 (100)
CHB no 99 39 39 (56.5) 9 (13.0) 21 (30.4) 69 (100)
yes 45 15 18 (60.0) 3 (10.0) 9 (30.0) 30 (100)
Total 144 54 57 (57.6) 12 (12.1) 30 (30.3) 99 (100)
All P >0.05
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in the Han nationality in Hunan, China had different
characteristics from those of Europeans. However, it had
similar findings with the studies in the people without
HCV infection in Chinese Taiwan and the mainland, and
in a Japanese population, with frequencies of allele C in
BESP exon 13 c.1331 of 75.6, 74.5 and 73.7%, respectively
[12–14]. Similar genetic background in Chinese and
Japanese supported the credibility of our findings.
Our research illustrated that the polymorphism of BSEP
SNP rs2287622 was statistically correlated with chronic
HCV infection in Han population aged 40 years and above.
Interestingly, the correlation was not found in HCV pa-
tients aged 18–<40 years. Many gene polymorphisms or
mutations, and their corresponding protein functions, and
even the presence of clinical features, are age specific. The
reasons for the age-related difference in frequency distribu-
tion of the alleles and genotypes of BSEP SNP rs2287622
were not included in this study. But further stratification
analysis found that there were no statistical differences in
the frequencies of the alleles and genotypes of BESP gene
SNP rs2287622 between males and females, among CHC
patients with different HCV genotypes, or between CHC
patients with and without liver cirrhosis. It is speculated
that BSEP might change the components of the bile acid
pool in serum and liver cells to modify the chronicity
process of HCV infection. Further study with a larger
cohort of research subjects is essential.
Conclusions
Among the Han individuals aged over 40 years in
Hunan, China, genotype CC or CT of BSEP gene SNP
rs2287622 may correlate with higher risk of CHC in
comparison with genotype TT. Further study with a
larger cohort is essential.
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